De Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie
Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Acadia Pharmaceuticals has received approval from the European Commission for DAYBU (trofinetide), marking it as the first and only treatment for neurological behavioral symptoms of Rett syndrome in the European Union. This approval applies to both adult and pediatric patients aged five and older, representing a significant milestone in treatment options for this condition.
Market Sentiment Analysis
POSITIVE FACTORS
DAYBU is the first and only approved treatment for Rett syndrome in the EU.
The approval marks a significant advancement for patients and families.
It addresses neurological behavioral symptoms in both adults and pediatric patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
5.6%
average across 7 past catalysts
Lead asset
Pimavanserin
Phase 2 · Agitation and Aggression in Alzheimer's Disease
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) heeft vandaag aangekondigd dat de Europese Commissie (EC) een handelsvergunning heeft verleend voor DAYBU (trofinetide) voor de behandeling van neurologische gedragssymptomen van het Rett-syndroom bij volwassenen en pediatrische patiënten van vijf jaar en ouder, waarmee het de eerste en enige goedgekeurde behandeling is voor deze indicatie in de Europese Unie (EU). “De goedkeuring van DAYBU is een belangrijke stap voorwaarts
Frequently Asked Questions
What is DAYBU approved for?
DAYBU is approved for treating neurological behavioral symptoms of Rett syndrome.
Who can use DAYBU?
DAYBU is approved for adults and pediatric patients aged five and older.
What significance does DAYBU's approval hold?
It is the first and only approved treatment for Rett syndrome in the EU.